Magnetoencephalography Market Report: Market Size & Forecast 2026

The global MEG market encompasses systems that detect and record the extremely weak magnetic fields produced by synchronized neuronal activity, enabling millisecond-temporal-resolution functional brain mapping without ionizing radiation. Market size estimates for the 2024-2025 base period range from approximately USD 255 million to USD 413 million across different analytical sources, reflecting differing scope definitions and estimation methodologies, while projections for the mid-2020s cluster around USD 391 million to USD 471 million. By the 2032-2035 horizon, published forecasts span roughly USD 570 million to over USD 1 billion, with compound annual growth rates generally falling between 6.8% and 10.2%, indicating a moderate-to-strong expansion consensus despite methodological variation across reports.

• •2024/2025 base market estimates range from ~USD 255M to ~USD 413M depending on source and scope
• •Forecasts for 2026 converge around USD 391M-471M, with projected 2032-2035 values spanning USD 570M-1,000M+
• •Reported CAGR range across sources: 4.4% to 10.2%, reflecting differing geographic coverage and segment inclusions
• •Primary clinical applications include pre-surgical epilepsy evaluation, functional brain mapping for neurosurgery, and neurodevelopmental disorder assessment

The increasing global burden of neurological disorders, including epilepsy, Alzheimer's disease, Parkinson's disease, and brain tumors, is driving demand for advanced neuroimaging modalities that provide superior spatial and temporal resolution compared to alternatives. MEG's non-invasive nature and absence of radiation exposure make it particularly attractive for repeated clinical monitoring and pediatric applications, where cumulative radiation exposure is a concern. Expanding neuroscience research programs, growing government and private funding for brain research initiatives, and the rise of multimodal imaging protocols that combine MEG with MRI or EEG are collectively broadening the addressable market beyond traditional clinical settings.

• •Rising prevalence of neurological disorders and aging populations increase demand for advanced diagnostic neuroimaging
• •MEG's non-invasive, radiation-free profile supports repeated use and pediatric applications versus ionizing modalities
• •Multimodal imaging integration with MRI and EEG expands clinical utility and research adoption
• •Expanding brain research funding (public and private) drives replacement cycles and new installations at academic medical centers

The market can be segmented by product type into complete MEG systems, individual system components such as sensor arrays and dewar units, and the magnetically shielded rooms essential for operation. By end user, demand splits between hospital and clinical neurology departments, academic and research institutions, and specialized diagnostic imaging centers. North America accounts for the largest share of current market revenue, attributed to well-established neurological research infrastructure, high healthcare spending, and early adoption of advanced neuroimaging technology. Europe holds the second-largest position, while the Asia-Pacific region is increasingly important as healthcare infrastructure expands and neurological research capacity grows in several large economies.

• •North America dominates market share, supported by advanced clinical infrastructure and high healthcare spending on neurology
• •Europe is the second-largest regional market, with established academic neuroscience programs and clinical MEG adoption
• •Asia-Pacific is an emerging growth region as healthcare infrastructure and neurological research investment expand
• •Key end-user segments: hospital neurology departments, academic research institutions, and specialized imaging centers

Who are the notable companies in the industry?

The global MEG market is characterized by a concentrated, specialty-driven structure in which a relatively small cohort of manufacturers competes on proprietary sensor technology, system integration depth, and after-sales service reach. **MEGIN** and **Compumedics Limited** occupy prominent positions as vertically integrated producers, offering full turnkey systems that combine SQUID-based sensor arrays with magnetically shielded rooms and neuroimaging software suites. **Ricoh Company, Ltd.** leverages its broader industrial engineering and optics expertise to differentiate its platform, while **CTF MEG NEURO INNOVATIONS, INC.** has carved a niche around co-registration and multi-modal neuroimaging integration. At the same time, newer entrants **FieldLine Inc.** and **Cerca Magnetics Limited** are pursuing more focused strategies, FieldLine with OPM-based sensor architectures and Cerca with compact, optically-pumped magnetometer technologies, aimed at reducing system footprint and operational complexity. Barriers to entry remain high given the capital intensity of SQUID manufacturing, the precision engineering demanded by shielded-room construction, and the rigorous regulatory pathways required for clinical deployment. Regional market access, in turn, is contingent on the ability to sustain local installation, calibration, and maintenance infrastructure, reinforcing the advantage of established players with proven global service networks. **(176 words)**

• •Market structure is concentrated with high barriers to entry driven by SQUID sensor technology, shielded room engineering, and regulatory requirements
• •Competitive dynamic spans vertically integrated full-system manufacturers and subsystem specialists, with differentiation rooted in sensor architecture and system integration
• •Primary technology routes are based on cryogenically cooled SQUID sensor arrays operating within liquid helium-cooled dewars, with optically-pumped magnetometer variants emerging
• •Regional capacity and service presence is concentrated in North America and Western Europe, with expanding capability in East Asia

What are the recent trends and outlook?

Looking forward, the MEG market is expected to continue its moderate-to-strong growth trajectory as technological improvements in sensor design reduce system complexity and operational costs, and as clinical evidence supporting MEG-guided interventions accumulates. The transition toward optically-pumped magnetometer (OPM) sensor technology, which operates at higher temperatures and with potentially lower infrastructure requirements, represents a significant technological shift that could broaden market accessibility by reducing dependence on large, immobile shielded rooms. Ongoing consolidation of multimodal imaging workflows, growing interest in MEG for psychiatric and neurodevelopmental disorder assessment, and continued expansion of epilepsy surgery programs in emerging healthcare systems are all expected to sustain demand growth through the end of the decade.

• •Optically-pumped magnetometer technology is emerging as a transformative alternative to traditional SQUID-based systems, with potential to reduce infrastructure requirements and enable wearable configurations
• •Multimodal imaging integration, combining MEG with MRI, EEG, and other modalities, is a key clinical and research trend expanding utilization
• •Expanding clinical indications beyond epilepsy into psychiatric, neurodevelopmental, and cognitive disorder assessment are broadening the addressable patient population
• •Market growth is expected to continue at a 7-10% annual rate through the early 2030s, contingent on technological cost reductions and expanding healthcare infrastructure investment